Bio-Techne Corporation (TECH) Stock Price & Analysis
Bio-Techne Corporation (TECH) closed at USD 72.62 on Thursday, October 22, 2026, down 0.03% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 72.64; the Oct 22, 2026 session ranged USD 72.51–72.69 on volume of 4,160,527 shares. Market capitalization is $11.39B, with a 52-week range of USD 43.2–72.69 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:23 UTC.
Also available as compact Markdown for AI agents: nexqual.com/TECH.md
Key facts (TECH)
- Last four reported quarters (through Jun 30, 2026): revenue $1.22B, net income $182M (15.0% margin), free cash flow $263M (SEC filings).
- Valuation: P/E 62.6x (avg 80.5x at the last 3 fiscal year-ends).
- 5 of 80 tracked superinvestors hold TECH (13F, Q2 2026): 0 new, 0 added, 5 reduced, 0 unchanged.
- Insider open-market sales, last ~7 months: 1 Form 4 filings, $320K; 1 not under a Rule 10b5-1 plan ($320K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Hold (mean 2.92 on a 1–5 scale) (13 analysts), mean target USD 70.5 (range 50–73).
- Total return with dividends: 1Y +10.6% vs S&P 500 +14.9%; 5Y -41.2% vs S&P 500 +80.3%.
- Next earnings: 2026-11-09, EPS estimate USD 0.45, revenue estimate $292M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (TECH)
| USD | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $1.11B | $1.14B | $1.16B | $1.22B | $1.22B | $1.22B |
| Gross profit | $756M | $770M | $770M | $790M | $799M | — |
| Operating income | $297M | $299M | $207M | $102M | $252M | $252M |
| Net income | $272M | $285M | $168M | $73.4M | $182M | $182M |
| EPS (diluted) | $1.66 | $1.76 | $1.05 | $0.46 | $1.16 | — |
| Free cash flow | $280M | $216M | $236M | $257M | $263M | $263M |
| Gross margin | 68.4% | 67.7% | 66.4% | 64.8% | 65.8% | — |
| Operating margin | 26.8% | 26.3% | 17.8% | 8.4% | 20.7% | 20.7% |
| Net margin | 24.6% | 25.1% | 14.5% | 6.0% | 15.0% | 15.0% |
| Revenue growth | +18.7% | +2.8% | +2.0% | +5.2% | -0.4% | — |
| Cash + short-term investments | $247M | $204M | $153M | — | — | — |
| Total debt | $256M | $350M | $319M | $346M | $200M | — |
Fiscal years end Jun. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (TECH)
P/E 62.6x · P/S 9.4x · P/FCF 43.3x · P/B 5.4x · FCF yield 2.31% · Earnings yield 1.60% · Dividend yield (paid, TTM) 0.44% · Buyback yield (TTM) 0.37%
P/E at fiscal year-ends: Jun 2026 61.0x, Jun 2025 112.0x, Jun 2024 68.5x.
Superinvestors (SEC 13F-HR, Q2 2026) (TECH)
5 of 80 tracked investors hold TECH. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Ruane Cunniff | Ruane Cunniff LP | 3.68% | $237M | Reduced -1.3% |
| Wallace Weitz | Weitz Investment Management | 2.66% | $38.4M | Reduced -16.8% |
| Mairs & Power | Mairs & Power Funds | 1.75% | $191M | Reduced -1.8% |
| Lee Ainslie | Maverick Capital | 0.98% | $108M | Reduced -67.6% |
| Henry Ellenbogen | Durable Capital Partners | 0.34% | $35.5M | Reduced -88.7% |
Insider sales (SEC Form 4, open-market, last ~7 months) (TECH)
0 of 1 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-05-08 | Herr Amy E. | Director | 6,636 | $320K | 69.7% | No | Too little history (no open-market trades in 2023 or 2024) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (TECH)
Consensus Hold (mean 2.92 on a 1–5 scale), 13 analysts; mean target USD 70.5 (low 50, high 73).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-13 | Wells Fargo | Downgrade | Overweight → Equal-Weight | $62 → $73 |
| 2026-07-09 | RBC Capital | Downgrade | Outperform → Sector Perform | $62 → $73 |
| 2026-06-30 | TD Cowen | Downgrade | Buy → Hold | $65 → $73 |
| 2026-06-30 | Benchmark | Downgrade | Buy → Hold | |
| 2026-06-29 | Citigroup | Downgrade | Buy → Neutral | $70 → $73 |
| 2026-06-26 | Stephens & Co. | Downgrade | Overweight → Equal-Weight | $68 → $73 |
| 2026-06-26 | William Blair | Downgrade | Outperform → Market Perform | |
| 2026-06-26 | Baird | Target raised | Neutral | $49 → $73 |
Total return (dividends reinvested) (TECH)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +10.6% | -41.2% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +10.6% | -10.1% |
| Volatility (annualized) | 43.5% | 39.2% |
| Max drawdown | -39.3% (Jan 2026→May 2026) | -66.3% (Oct 2021→May 2026) |
TECH revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Protein Sciences | $231.2M | 71.9% | +2.1% |
| Diagnostics & Spatial Biology | $90.1M | 28.1% | +0.5% |
| Total revenue | $321.3M | 100% | — |
TECH revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Product & Services | $315.3M | 98.1% | +1.2% |
| — Consumables (part of Product & Services) | $260.7M | 81.1% | +3.1% |
| — Instruments (part of Product & Services) | $31.5M | 9.8% | +9.1% |
| — Service (part of Product & Services) | $23.1M | 7.2% | -22.1% |
| Royalty | $5.9M | 1.8% | +6.5% |
| Total revenue | $321.3M | 100% | — |
TECH revenue by region (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| United States | $166.1M | 51.7% | -5.8% |
| EMEA Excluding UK | $80.3M | 25.0% | +14.1% |
| China | $26.9M | 8.4% | +0.0% |
| APAC Excluding Greater China | $22.1M | 6.9% | +17.0% |
| United Kingdom | $14.5M | 4.5% | -2.2% |
| Rest Of World | $11.3M | 3.5% | +17.4% |
| Total revenue | $321.3M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
TECH suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Customer | Techne | “The majority of Bio-Techne Diagnostic division's sales are through OEM agreements, but we sell some of our diagnostic reagent products directly to customers and, in Europe and Asia, also through distributors.” |
| Customer | FedEx (FDX) | “Consequently, we ship a significant portion of our products to our customers by express mail or air delivery through package delivery companies, such as FedEx in the U.S. and DHL in Europe.” |
| Partner | Merck (MRK) | “On June 25, 2026, the Company entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent") and EMD Holdings NewCo, Inc. ("Merger Sub"), a Minnesota corporation and a wholly-owned subsidiary of Parent.” |
| Partner | Wilson Wolf | “Through a collaborative marketing venture with Wilson Wolf, we have leveraged the products we have or are developing to provide a more complete offering for the cell and gene therapy market.” |
| Partner | Thermo Fisher (TMO) | “We sell our products directly to customers who are primarily located in North America, Europe and China, as well as through a distribution agreement with Thermo Fisher Scientific.” |
| Partner | ScaleReady | “We have also continued participating in our collaborative marketing venture, ScaleReady LLC, with Wilson Wolf and another partner, which addresses the needs of the rapidly expanding cell and gene therapy market.” |
Quoted from the company's 10-K filed Aug 24, 2026.
Companies that name TECH in their SEC reports
| Relationship to TECH | Company | Filing | Sentence |
|---|---|---|---|
| partner | Wave Life Sciences, Inc. (WVE) | 10-K Feb 26, 2026 | “In November 2019, we entered into an agreement with Asuragen (which was acquired by Bio-Techne Corporation in April 2021), a molecular diagnostics company, for the development and potential commercialization of companion diagnostics for our investigational allele-selective therapeutic programs targeting HD.” |
TECH analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.45 | $0.44 | +1.9% | $292.2M | 7 |
| Next quarter (ends Dec 2026) | $0.48 | $0.48 | -0.2% | $307.8M | 6 |
| Current fiscal year (ends Jun 2027) | $2.04 | $2.05 | -0.4% | $1.27B | 13 |
| Next fiscal year (ends Jun 2028) | $2.31 | $2.30 | +0.5% | $1.40B | 9 |
TECH options: expected move
Options price a move of about ±3.8% (±$2.75) by Nov 20, 2026, which includes earnings on Nov 9, 2026. Over the last 8 reports the stock moved ±4.6% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 10.4% | ±3.8% |
| Jan 15, 2027 | 84 | 5.1% | ±3.6% |
| Mar 19, 2027 | 147 | 3.3% | ±3.4% |
| Jun 17, 2027 | 237 | 2.9% | ±3.5% |
30-day implied volatility 6% vs 1.8% realized over the last 30 trading days. Put/call ratio (volume) 3.02. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:23 UTC)
| Price | USD 72.62 |
|---|---|
| Change | ▼ 0.03% (down) |
| Previous Close | USD 72.64 |
| Open | USD 72.56 |
| Day Range | USD 72.51 – 72.69 |
| 52-Week Range | USD 43.2 – 72.69 |
| Volume | 4,160,527 shares |
| Market Cap | $11.39B |
| Exchange | NMS |
Technical Analysis (TECH)
Nexqual's technical model rates TECH "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 23, 2026 at 09:23 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 56.41 (neutral) |
| vs SMA50 | Above (USD 72.41) |
| MACD | 0.09 (positive) |
Analyst Ratings (TECH)
Wall Street analysts rate TECH "Hold" based on 13 analysts, with a mean price target of USD 70.5 (range USD 50–73), per Nexqual as of October 23, 2026 at 09:23 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 13 |
| Mean Target | USD 70.5 |
| High Target | USD 73 |
| Low Target | USD 50 |
| Buy / Hold / Sell | 1 / 12 / 0 |
Earnings (TECH)
| Next Earnings Date | 2026-11-09 |
|---|---|
| EPS Estimate | USD 0.45 |
| Revenue Estimate | $292.20M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.52 vs est 0.52 ▲ beat |
| 2026-03-31 | USD 0.53 vs est 0.53 ▼ miss |
| 2025-12-31 | USD 0.46 vs est 0.43 ▲ beat |
| 2025-09-30 | USD 0.42 vs est 0.42 ▼ miss |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Financials & Fundamentals (TECH)
| Total Revenue | $1.22B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +1.30% |
| Gross Margin | +66.24% |
| Operating Margin | +27.87% |
| Profit Margin | +14.97% |
| ROE | +9.03% |
| Debt / Equity | 0.14 |
| Current Ratio | 4.55 |
| Total Cash | $265.48M |
| Total Debt | $289.09M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $263.22M (21.7% of revenue) |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Financial Health Score (TECH)
Nexqual rates Bio-Techne Corporation's overall financial health "Solid" across five dimensions, as of October 23, 2026 at 09:23 UTC.
| Growth | Weak — Revenue -0% YoY (annual), declining |
|---|---|
| Profitability | Strong — Gross margin 66%, operating 28% (last 12 months) |
| Balance Sheet | Strong — $265M cash vs $289M debt |
| Cash Flow | Strong — FCF $263M (last 4 quarters to Jun 2026, SEC), 22% margin |
| Efficiency | Mixed — ROE 9%, ROA 6.7% |
Ownership (TECH)
| Insider Ownership | +0.34% |
|---|---|
| Institutional Ownership | +114.13% |
| Shares Outstanding | 156.82M |
| Float | 156.15M |
| Short % of Float | +4.72% |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Leadership (TECH)
Bio-Techne Corporation is led by Kim Kelderman, CEO, President & Director, per Nexqual as of October 23, 2026 at 09:23 UTC.
| CEO, President & Director | Kim Kelderman |
|---|---|
| Executive VP of Finance & CFO | James T. Hippel |
| President of Protein Sciences Segment | William A. Geist |
| VP & CTO | Gary J. Latham |
| Vice President of Investor Relations | David Clair C.F.A. |
Major Backers & Investors (TECH)
Notable institutional backers of Bio-Techne Corporation include FMR, LLC, Goldman Sachs, HBK Investments L P, according to Nexqual as of October 23, 2026 at 09:23 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 8.16% |
| Goldman Sachs | 4.68% |
| HBK Investments L P | 4.35% |
| Morgan Stanley | 4.07% |
| Invesco | 3.18% |
| SmallCap World Fund Inc | 2.29% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 10.67% |
| BlackRock | 8.94% |
| State Street | 3.81% |
| Geode Capital | 3.41% |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
From Bio-Techne Corporation's Latest SEC 10-K Filing (filed 2026-08-24)
Key Strengths & Strategy (as disclosed to the SEC)
- Where we have been contacted by patent holders with certain intellectual property rights, Bio-Techne typically has entered into licensing agreements with patent holders under which it has the exclusive and/or non-exclusive right to use patented technology as well as the right to manufacture and sell certain patented products to the research and/or diagnostics markets.
- We have taken steps to protect our intellectual property and proprietary technology, in part by entering into confidentiality agreements and intellectual property assignment agreements with our employees, consultants, corporate partners and, when needed, our advisors.
- We will continue to leverage our strong balance sheet to gain access to new and differentiated technologies and products that improve our competitiveness in the current market, meet customers' expanding workflow needs and allow us to enter adjacent markets.
Partnerships
- We sell our products directly to customers who are primarily located in North America, Europe and China, as well as through a distribution agreement with Thermo Fisher Scientific.
Legal & Regulatory Risks (Item 1A, quoted)
- Our business is subject to extensive regulation; failure to comply with these regulations could adversely affect our business and financial results.
- Our business and financial results can be impaired by improper conduct by any of our employees, agents or business partners.
- Government authorities may conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law.
- Failure to comply with privacy and security laws and regulations could result in fines, penalties and damage to the Company's reputation and have a material adverse effect upon the Company's business, a risk that has been elevated with recent acquisitions that use protected health information and utilize healthcare providers for laboratory testing services.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CORT | Corcept Therapeutics Incorporat | USD 107.5 | ▼ 7.55% |
| BMRN | BioMarin Pharmaceutical Inc. | USD 56.63 | ▲ 2.57% |
| MDGL | Madrigal Pharmaceuticals, Inc. | USD 453.34 | ▼ 1.01% |
| SMMT | Summit Therapeutics Inc. | USD 15.55 | ▼ 1.77% |
| PCVX | Vaxcyte, Inc. | USD 62.85 | ▼ 0.6% |
| BBIO | BridgeBio Pharma, Inc. | USD 68.12 | ▲ 0.56% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:23 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt